Research & Development

OZMOSI and Planview partner to enhance pharmaceutical data integration

OZMOSI and Planview have formed a partnership to support pharmaceutical organisations by integrating Ozmosi’s structured, machine-readable clinical datasets with Planview’s AI-driven portfolio planning platform.

Cumberland to sell drug portfolio to Apotex for $100m

Cumberland Pharmaceuticals has agreed to sell its branded commercial drug portfolio to Canadian pharmaceutical company Apotex for $100m in cash.

Sanofi receives FDA approval for Tzield in paediatric diabetes

Sanofi has received approval from the US Food and Drug Administration (FDA) for a supplemental biologic licence application for Tzield (teplizumab-mzwv), allowing its use to delay stage 3 type 1 diabetes (T1D) onset in children as young as one year diagnosed with stage 2 T1D.

MSD teams up with Google Cloud on agentic AI transformation

Merck & Co (MSD) and Google Cloud have formed a multi-year partnership, investing up to $1bn, to advance agentic AI enterprise transformation.

BioAegis and Prenosis partner for inflammatory disease therapies

BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases.

Health Canada approves Biocon’s two denosumab biosimilars

Biocon has received a Notice of Compliance from Health Canada for Bosaya (denosumab) and Vevzuo (denosumab), both biosimilars referencing Prolia and Xgeva, respectively.

Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy

Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their supplemental biologics licence application (sBLA) for perioperative Padcev (enfortumab vedotin-ejfv) combined with the PD-1 inhibitor Keytruda (pembrolizumab) for muscle-invasive bladder cancer (MIBC).

Asahi Kasei acquires German company Aicuris

Asahi Kasei has completed its acquisition of Aicuris Anti-infective Cures, a German biopharmaceutical company.

UCB to purchase Neurona and NRTX-1001 for $1.15bn

UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio.